Loading stock data…
ZBH
$89.63+2.36 (+2.70%)
Market ClosedLast close Jun 9
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zimmer Biomet Holdings, Inc. in the Healthcare sector is trading at $89.63 with a market capitalization of $16.4B. Wall Street consensus targets $98.70 (20 analysts), implying a +10.1% move over the next 12 months. The stock is currently 17% below its 52-week high of $108.29, remaining 3.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +10.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$89.63
Potential Upside
29.2%
Whystock Fair Value$115.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Hold
Mean target$98.70+10.1%
Range$83.00 – $130.00
Fundamentals
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.02
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.07%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.01%
Volume
Today's trading volume
1.43M
Recent News
Why Is Perrigo (PRGO) Down 9% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How Financial Strength Remains a Key Advantage for GMED
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
2 Profitable Stocks to Consider Right Now and 1 We Question
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
GE HealthCare (GEHC) Up 3.3% Since Last Earnings Report: Can It Continue?
GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.